Want to see AGEN full AI Analyst Report?
AGEN Stock Chart & Stats
$8.36
$0.07(1.17%)
At close: 4:00 PM EDT
$8.36
$0.07(1.17%)
Day’s Range― - ―
52-Week Range$2.71 - $10.31
Previous CloseN/A
Volume97.68K
Average Volume (3M)1.09M
Market Cap
$289.94M
Enterprise Value$391.15M
Total Cash (Recent Filing)$18.74M
Total Debt (Recent Filing)$40.71M
Price to Earnings (P/E)2.4
Beta2.01
Next Earnings
Nov 10, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.72
Shares Outstanding45,161,915
10 Day Avg. Volume903,505
30 Day Avg. Volume1,086,647
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit2.96
Enterprise Value/Ebitda2.51
Forecast
1Y Price Target
$24.50Price Target Upside193.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.25
Revenue Forecast (FY)$124.45M
Bulls Say, Bears Say
Bulls Say
Revenue And Profit TurnaroundThe sharp increase in revenue and move to substantial reported profitability demonstrate meaningful recent operating improvement. If Agenus can sustain demand, collaboration activity, and development progress, the stronger earnings base could support reinvestment and improve its strategic position over the next several quarters.
Debt ReductionThe substantial reduction in total debt lowers absolute repayment obligations and can improve financial flexibility compared with the prior year. Although the balance sheet remains constrained, reduced leverage may help Agenus allocate more resources toward clinical development and negotiate future financing from a stronger position.
Strengthened Board ExpertiseAdding a director with legal, capital markets, cross-border, and biotechnology transaction experience strengthens oversight relevant to Agenus’s complex strategic needs. This expertise may improve governance and execution as the company manages financing, partnerships, international dealings, and development activities.
Bears Say
Negative Shareholder EquityNegative shareholder equity signals that accumulated losses have eroded the company’s capital base and limits financial flexibility. It can make future funding more challenging, increase reliance on external capital, and heighten dilution or refinancing risk while Agenus continues funding its pipeline.
Persistent Cash BurnAgenus continues to consume substantial cash despite an improvement from 2025, so reported profitability has not yet translated into cash generation. Persistent negative operating and free cash flow may require additional financing and can constrain investment, development priorities, and shareholder outcomes.
Dilutive High-cost FinancingThe amended financing carries a high 13% interest rate and uses common stock to satisfy part of the extension fee, demonstrating costly and potentially dilutive funding. Continued reliance on these structures can increase financing expense and dilute existing holders while the company remains cash consumptive.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $2.71 and its highest was $10.31 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $289.94M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.045 by -$0.055.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.28.
How many shares outstanding does Agenus have?
Agenus has 45,161,915 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.045. Following the earnings report the stock price went down -3.728%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (193.06% Upside)
$24.50 (193.06% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 71%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.74%
12-Months-Change
Fundamentals
Return on Equity
-38.12%
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$24.50
▲(193.06% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
1.79% Insiders
9.30% Mutual Funds
0.11% Other Institutional Investors
80.48% Public Companies and
Individual Investors